Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2024-01-30FDA Approved: PLERIXAFOR — Supplemental Application (Dr. Reddy's Laboratories Inc)
FDA approved a supplemental application for plerixafor from Dr. Reddy's Laboratories, typically resulting in a labeling or usage modificatio…
-
FDA approval · 2024-01-30FDA Approved: PLERIXAFOR — Supplemental Application (Zydus Lifesciences Limited)
FDA approves a supplemental application for Plerixafor submitted by Zydus Lifesciences Limited.
-
FDA approval · 2024-01-11FDA Approved: BELRAPZO — Supplemental Application (Eagle Pharmaceuticals, Inc)
The FDA approved a supplemental application for Belrapzo (bendamustine hydrochloride) submitted by Eagle Pharmaceuticals, Inc. The action up…
-
FDA approval · 2023-09-08FDA Approved: APHEXDA — Original Application (Gamida Cell Inc.)
FDA approved APHEXDA (motixafortide) from Gamida Cell as a new drug to mobilize hematopoietic stem cells in adults with multiple myeloma or …
-
FDA approval · 2023-07-26FDA Approved: PLERIXAFOR — Original Application (Zydus Lifesciences Limited)
FDA approved the original generic application for Plerixafor, enabling Zydus Lifesciences Limited to market the drug in the United States.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-07-24FDA Approved: PLERIXAFOR — Original Application (Meitheal Pharmaceuticals Inc.)
FDA approved a generic version of plerixafor (Meitheal Pharmaceuticals) via an Original Application, enabling broader access for hematopoiet…
-
FDA approval · 2023-07-24FDA Approved: PLERIXAFOR — Original Application (Dr. Reddy's Laboratories Inc)
FDA approved the original application for a generic Plerixafor (PLERIXAFOR) manufactured by Dr. Reddy's Laboratories Inc.
-
FDA approval · 2023-07-24FDA Approved: PLERIXAFOR — Original Application (Novadoz Pharmaceuticals LLC)
FDA approved a generic version of Plerixafor (Novadoz Pharmaceuticals LLC) under an Original Application (ANDA) for mobilizing hematopoietic…
-
FDA approval · 2023-07-24FDA Approved: PLERIXAFOR — Original Application (Eugia US LLC)
FDA approved the original abbreviated new drug application for Plerixafor by Eugia US LLC, enabling its generic entry for stem cell mobiliza…
-
FDA approval · 2022-12-07FDA Approved: BENDAMUSTINE HYDROCHLORIDE — Original Application (Apotex Corp)
FDA approved bendamustine hydrochloride via Apotex Corp's original application, indicating the approval of a Bendamustine HCl product.
-
FDA approval · 2022-11-29FDA Approved: JYLAMVO — Original Application (SHORLA ONCOLOGY INC.)
FDA approved JYLAMVO (methotrexate) under an Original Application from SHORLA ONCOLOGY INC.
-
FDA approval · 2022-06-03FDA Approved: RIABNI — Supplemental Application (Amgen, Inc)
FDA approved a supplemental application for RIABNI (rituximab-arrx) from Amgen. The action updates RIABNI’s labeling to reflect its approved…
-
FDA approval · 2021-12-02FDA Approved: RITUXAN — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for Rituxan (rituximab) filed by Genentech, Inc., resulting in updated labeling for the product.
-
FDA approval · 2021-10-25FDA Approved: METHOTREXATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Methotrexate by Hikma Pharmaceuticals USA Inc. (ANDA089342).
-
FDA approval · 2021-06-14FDA Approved: TREXALL — Supplemental Application (Teva Women's Health, Inc.)
The FDA approved a supplemental application for TREXALL (methotrexate) filed by Teva Women's Health, Inc.
-
FDA approval · 2021-04-30FDA Approved: CARMUSTINE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved a supplemental application for Carmustine submitted by Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. This actio…
-
FDA approval · 2021-01-14FDA Approved: VINCRISTINE SULFATE — Supplemental Application (Hospira, Inc.)
The FDA approved a supplemental application filed by Hospira for vincristine sulfate, a generic vincristine product.
-
FDA approval · 2020-12-17FDA Approved: RIABNI — Original Application (Amgen, Inc)
FDA approved RIABNI (rituximab-arrx) from Amgen as a biosimilar to rituximab via Original Application.
-
FDA approval · 2020-06-26FDA Approved: CYTARABINE — Original Application (Meitheal Pharmaceuticals Inc.)
FDA approval of Meitheal Pharmaceuticals' original ANDA for Cytarabine (cytarabine), a generic injectable anticancer agent.
-
FDA approval · 2020-05-05FDA Approved: RITUXAN HYCELA — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for Rituxan HYCELA (rituximab and hyaluronidase) from Genentech, expanding its approval through …
-
FDA approval · 2020-01-30FDA Approved: METHOTREXATE — Original Application (Chartwell RX, LLC)
FDA approvedChartwell RX, LLC's methotrexate product under an Original Application, making a new generic version of methotrexate available. …
-
FDA approval · 2019-11-21FDA Approved: TREANDA — Supplemental Application (Cephalon, LLC)
The FDA approved a supplemental application for TREANDA (bendamustine hydrochloride) submitted by Cephalon, LLC.
-
FDA approval · 2019-07-23FDA Approved: RUXIENCE — Original Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved Ruxience (rituximab-pvvr) from Pfizer as a biosimilar to rituximab, under an original application; the approval covers multiple…
-
FDA approval · 2019-05-30FDA Approved: MOZOBIL — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approved a supplemental application for Mozobil (plerixafor) by Sanofi-Aventis U.S. LLC. The approval expands the indication to mobilize…
-
FDA approval · 2019-05-23FDA Approved: TRUXIMA — Supplemental Application (Cephalon, Inc.)
FDA approved a supplemental application for TRUXIMA (rituximab-ABBS) submitted by Cephalon, Inc.